{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:46:13Z","timestamp":1783464373526,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.atherosclerosis.2024.117550","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:31:46Z","timestamp":1713195106000},"page":"117550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-6731","authenticated-orcid":false,"given":"Ingrid","family":"Engebretsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"St\u00f8vring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Husebye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Sverre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toril","family":"Dammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Munkhaugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.117550_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib2","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5324\/nje.v29i1-2.4052","article-title":"Persistence of statin treatment \u2013 the impact of analytic method when estimating drug survival","volume":"29","author":"Francisco","year":"2021","journal-title":"Norsk Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib7","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ehjcvp\/pvaa010","article-title":"Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54 872 patients","volume":"7","author":"Khalaf","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","article-title":"Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients","volume":"332","author":"Schiele","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12872-020-01368-6","article-title":"Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population","volume":"20","author":"Sverre","year":"2020","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MLR.0b013e3181c132ad","article-title":"Patient, physician, and payment predictors of statin adherence","volume":"48","author":"Chan","year":"2010","journal-title":"Med. Care"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jacl.2013.09.008","article-title":"Register-based predictors of adherence among new statin users in Finland","volume":"8","author":"Aarnio","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ehjcvp\/pvac064","article-title":"Initial statin dose after myocardial infarction and long-term cardiovascular outcomes","volume":"9","author":"Kyt\u00f6","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12872-016-0283-6","article-title":"Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction","volume":"16","author":"Halvorsen","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117550_bib16","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD)--new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"K","year":"2008","journal-title":"Norsk epidemiologi"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/14017431.2015.1111408","article-title":"The role of medical and psychosocial factors for unfavourable coronary risk factor control","volume":"50","author":"Munkhaugen","year":"2016","journal-title":"Scand. Cardiovasc. J."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2125.2010.03895.x","article-title":"Statin adherence and the risk of major coronary events in patients with diabetes: a nested case\u2013control study","volume":"71","author":"Ruokoniemi","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/PPA.S60927","article-title":"The association of smoking with medical treatment adherence in the workforce of a large employer","volume":"8","author":"Sherman","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac070","article-title":"Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs","volume":"2","author":"Engebretsen","year":"2022","journal-title":"European Heart Journal Open"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1345\/aph.1P607","article-title":"Estimates of statin discontinuation rates are influenced by exposure and outcome definitions","volume":"45","author":"Geers","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"European Heart Journal 2019"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237057","article-title":"Achievement of low-density lipoprotein cholesterol targets in cardiac rehabilitation: impact of the 2019 ESC\/EAS dyslipidaemia guidelines","volume":"11","author":"Haegele","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib24","series-title":"Department of Cardiology","article-title":"SWEDEHEART annual report","year":"2023"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib26","article-title":"Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events","volume":"11","author":"Zhan","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib27","article-title":"[PCSK9 inhibitors on reimbursable prescription: who is eligible?]","volume":"143","author":"Semb","year":"2023","journal-title":"Tidsskr. Nor. Laegeforen"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1119146","article-title":"Risk of recurrent cardiovascular events in coronary artery disease patients with Type D personality","volume":"14","author":"Torgersen","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jpsychores.2017.02.015","article-title":"Emotional distress as a predictor of statin non-adherence among Swedish first-time myocardial infarction patients, 2006-2013","volume":"97","author":"Liss\u00e5ker","year":"2017","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/PPA.S182765","article-title":"Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk","volume":"13","author":"Katzmann","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib31","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1525-1497.2006.00586.x","article-title":"Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes","volume":"21","author":"Kronish","year":"2006","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib32","first-page":"Cd004371","article-title":"Interventions to improve adherence to lipid-lowering medication","volume":"12","author":"van Driel","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1524-4733.2010.00774.x","article-title":"The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications","volume":"13","author":"Chapman","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib34","first-page":"E966","article-title":"The relationship between illness perception and medication adherence in patients with diabetes mellitus type II: illness perception and medication adherence","volume":"62","author":"Bilondi","year":"2021","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.atherosclerosis.2024.117550_bib35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.pec.2016.01.020","article-title":"Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis","volume":"99","author":"Miller","year":"2016","journal-title":"Patient Educ. Counsel."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:13:48Z","timestamp":1714018428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"alternative-id":["S0021915024001102"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117550","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117550"}}